Overview

Avelumab in G3 NEC

Status:
Completed

Trial end date:
2020-03-12

Target enrollment:

Participant gender:

Summary

This is a single-center, single-arm, open-label, pilot trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 3, poorly-differentiated neuroendocrine.carcinoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sunnybrook Health Sciences Centre

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Avelumab